Comparison of the expression and immunogenicity of wild-type and sequence-modified HIV-1 gag genes in a recombinant sendai virus vector

Current HIV Research

Volumn 8, Issue 3, 2010, Pages 199-206

  Yu, Shuangqing ^a   Feng, Xia ^a   Shu, Tsugumine ^b   Matano, Tetsuro ^c   Hasegawa, Mamoru ^b   Wang, Xiaoli ^d   Li, Hongxia ^a   Li, Zelin ^d   Zhong, Rugang ^d   Zeng, Yi ^a,d  

^a NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION   (China)

^b University of Tokyo   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Gag gene; HIV 1; Sendai virus; Vaccine

Indexed keywords

ANTIVIRUS AGENT; GAG PROTEIN; NEUTRALIZING ANTIBODY; PLASMID DNA; PRIMER DNA; VIRUS VACCINE; VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MUTANT PROTEIN; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA TRANSFECTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN MODIFICATION; SENDAI VIRUS INFECTION; VIRUS ISOLATION; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY; MONONUCLEAR CELL; PLASMID; SENDAI VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENETIC VECTORS; HIV-1; IMMUNIZATION, SECONDARY; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MUTANT PROTEINS; PLASMIDS; RECOMBINANT PROTEINS; SENDAI VIRUS;

EID: 77954079072     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791111133     Document Type: Article

References (24)

1. Leligdowicz A, Yindom LM, Onyango C, et al. Robust Gagspecific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest 2007; 117: 3067-74.
2. Geldmacher C, Currier JR, Herrmann E, et al. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. J Virol 2007; 81: 2440-8.
3. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13: 46-53.
4. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76: 10155-68.
5. Andre S, Seed B, Eberle J, et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72: 1497-503.
6. zur Megede J, Chen MC, Doe B, et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000; 74: 2628-35.
7. Ferrari S, Griesenbach U, Shiraki-Iida T, et al. A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther 2004; 11: 1659-64.
8. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74: 6564-9.
9. Shiotani A, Fukumura M, Maeda M, et al. Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Ther 2001; 8: 1043-50.
10. Yu D, Shioda T, Kato A, et al. Sendai virus-based expression of HIV-1 gp120: reinforcement by the V(-) version. Genes Cells 1997; 2: 457-66.
11. Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199: 1709-18.
12. Takeda A, Igarashi H, Nakamura H, et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 2003; 77: 9710-5.
13. Ma HX, Yu XH, Jiang CL, Wu YG, Kong W. Construction of Eukaryotic Expression Vector and Screening of Cell Strain for Stable Expression of HIV-1 Subtype B /C Env. Chinese J Biol 2006; 19: 365-7.
14. Yu S, Feng X, Shu T, et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 2008; 26: 6124-31.
15. Haglund K, Leiner I, Kerksiek K, et al. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses. J Virol 2002; 76: 2730-8.
16. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHCbinding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 1998; 161: 2985-93.
17. Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine 2001; 19: 2803-11.
18. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, Pavlakis GN. rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc Natl Acad Sci USA 1989; 86: 1495-9.
19. Casimiro DR, Tang A, Perry HC, et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol 2002; 76: 185-94.
20. Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997; 71: 4892-903.
21. Bitzer M, Armeanu S, Lauer UM, Neubert WJ. Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med 2003; 5: 543-53.
22. Kong W, Tian C, Liu B, Yu XF. Stable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vector. J Virol 2002; 76: 11434-9.
23. Matano T, Kano M, Nakamura H, Takeda A, Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen. J Virol 2001; 75: 11891-6.
24. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29: 1009-21.